WILMINGTON, Del., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage ...

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...

Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorpora PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session ...

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $1.00. The company’s shares closed yesterday at ...

WILMINGTON, Del., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the ...

Prelude Therapeutics Inc (NASDAQ:PRLD), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, finds itself at a critical juncture as it ...

Prelude Therapeutics Inc (NASDAQ:PRLD), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, finds itself at a critical juncture as it approaches ...